電気生理学デバイス市場：タイプ別、適応症別、エンドユーザー別、地域別、2026年～2032年

電気生理学デバイス市場の評価-2026年～2032年

心血管疾患、特に心房細動の罹患率の増加が電気生理学デバイスの需要を牽引しています。したがって、心血管系疾患、特に心房細動の有病率の増加は、市場規模の成長を急増させ、2024年には86億米ドルを超え、2032年までには193億1,000万米ドルの評価額に達します。

高齢者人口の増加は不整脈の発生を増加させ、電気生理学デバイスの需要を押し上げます。したがって、高齢者人口の増加により、市場は2026年から2032年にかけてCAGR11.73％で成長します。

電気生理学デバイス市場定義/概要

電気生理学デバイスは、心臓の不整脈やその他の電気的異常の診断と治療において重要な役割を果たしています。これらの高度な医療機器は、心臓の電気的活動を測定・分析するように設計されており、ヘルスケア専門家、特に心臓専門医や電気生理学者に重要な情報を提供します。これらの機器の主な機能は、異常な心臓のリズムを特定し、心臓内の不整脈発生部位を突き止め、適切な心臓機能を回復させるための治療的介入を行うことを支援することです。

電気生理学デバイスには、アブレーション用カテーテル、診断用カテーテル、マッピングシステム、3D電気解剖学的マッピングシステムなど、幅広いツールが含まれます。診断用カテーテルは心臓の電気インパルスを測定するのに役立ち、アブレーション用カテーテルは異常な心臓のリズムを治療するために特定の部位にエネルギーを供給するのに用いられます。マッピングシステムは心臓の電気的活動をリアルタイムで可視化し、正確な診断と的確な治療に役立ちます。

電気生理学デバイスの進歩は心臓治療に革命をもたらし、カテーテルを用いたアブレーションのような低侵襲の手技を可能にしました。これらの処置は、患者に従来の開心術に代わる選択肢を提供し、回復時間を大幅に短縮して治療成績を向上させます。心臓疾患がより一般的になるにつれて、電気生理学デバイスの需要は増加すると予想され、現代の心臓血管医療において不可欠なツールとなっています。

カテーテルアブレーション治療の普及が電気生理学デバイス市場の成長を加速させる？

低侵襲治療への選好の高まりが、電気生理学デバイスの主要な用途であるカテーテルアブレーションの採用を後押ししています。2021年にJAMA Network Openに掲載された研究によると、米国では2010年から2018年の間に心房細動に対するカテーテルアブレーションの使用が51%増加しました。医療費の増加と医療インフラの改善に起因します。特に新興国におけるヘルスケア支出の増加は、高度電気生理学デバイスの採用を促進しています。世界銀行の報告によると、GDPに占める世界のヘルスケア支出の割合は2010年の9.7%から2019年には9.9%に増加しており、ヘルスケア技術への投資が拡大していることを示しています。

病院外での用途が拡大しています。遠隔患者モニタリングのためのポータブルおよびウェアラブル電気生理学デバイスの使用が増加しており、新たな市場機会が生まれています。Verified Market Researchの調査レポートによると、心臓モニタリング機器を含む遠隔患者モニタリング市場は、2023年に417億7,000万米ドルと評価され、2026年から2032年までのCAGRは20%成長し、2032年までには1,583億9,000万米ドルに達すると予測されています。さらに、電気生理学技術の絶え間ない革新により、これらの機器の機能と用途が拡大しています。FDAは2021年に132の新しい医療機器を承認しましたが、その多くは心臓血管領域でした。

電気生理学的処置とデバイスの高コストは電気生理学デバイス市場の成長をどのように阻害するか？

電気生理学的処置やデバイスの高価な性質は、特に新興国において市場の成長を制限する可能性があります。2021年にJournal of Atrial Fibrillationに発表された研究によると、米国における心房細動に対するカテーテルアブレーションの平均費用は、使用する技術やヘルスケア環境にもよりますが、18,000ドルから32,000ドルでした。複雑な電気生理学的処置を行う訓練を受けた専門家の不足が市場拡大を抑制しています。Heart Rhythm Societyによる2022年の報告書によると、米国には3億3,000万人以上の人口に対応する心臓電気生理学の専門医が約3,500人しかいません。これは人口9万4,000人あたり約1人の電気生理学者がいることになり、大幅な不足を示しています。

電気生理学的治療中に有害事象が発生する可能性があるため、患者やヘルスケアプロバイダーの中には、その可能性を躊躇する者もいます。2020年にEuropean Heart Journalに発表された大規模研究によると、カテーテルアブレーション治療全体の合併症発生率は5.5％で、患者の1.7％が重大な合併症を経験していました。新しい電気生理学デバイスに対する長くて複雑な規制経路が市場の成長を鈍らせます。U.S. FDAは2022年の年次業績報告書で、医療機器の市販前承認（PMA）申請の決定までの平均期間が365日であったと報告しています。このタイムラインの延長は、新しい電気生理技術の市場導入を大幅に遅らせます。

目次

第1章 電気生理学デバイスの世界市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧
• 市場の魅力

第4章 電気生理学デバイスの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 電気生理学デバイスの世界市場：タイプ別

• 概要
• アブレーション用カテーテル
• 診断用カテーテル
• 検査機器
• マッピングシステム
• アクセサリー
• その他

第6章 電気生理学デバイスの世界市場：適応症別

• 概要
• 心房細動
• 上室性頻拍（SVT）
• 心室頻拍
• その他

第7章 電気生理学デバイスの世界市場：最終用途別

• 概要
• 病院
• 外来手術センター
• その他

第8章 電気生理学デバイスの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 電気生理学デバイスの世界市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略
• ACEマトリックス

第10章 企業プロファイル

• Siemens AG
• Medtronic Plc
• Abbot Laboratories
• GE Healthcare
• Boston Scientific Corporation
• Biosense Webster, Inc.
• Nihon Kohden Corporation
• Biotronik SE & CO. KG
• Koninklijke Philips N.V.
• Microport Scientific Corporation

第11章 主な発展

• 製品の上市/開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第12章 付録

• 関連調査

Electrophysiology Devices Market Valuation - 2026-2032

The rising incidence of cardiovascular diseases, particularly atrial fibrillation, is driving the demand for electrophysiology devices. Thus, the increasing prevalence of cardiovascular diseases, especially atrial fibrillation surged the growth of market size surpassing USD 8.6 Billion in 2024 to reach the valuation of USD 19.31 Billion by 2032.

Increasing geriatric population increases the incidences of cardiac arrhythmias increases, boosting the demand for electrophysiology devices. Thus, the growing aging population enables the market to grow at a CAGR of 11.73% from 2026 to 2032.

Electrophysiology Devices Market: Definition/ Overview

Electrophysiology devices play a critical role in the diagnosis and treatment of cardiac arrhythmias and other electrical abnormalities of the heart. These sophisticated medical instruments are designed to measure and analyze the heart's electrical activity, providing vital information to healthcare professionals, particularly cardiologists and electrophysiologists. The primary function of these devices is to identify abnormal heart rhythms, pinpoint arrhythmogenic areas within the heart, and assist in delivering therapeutic interventions to restore proper cardiac function.

Electrophysiology devices encompass a wide range of tools, including ablation catheters, diagnostic catheters, mapping systems, and 3D electroanatomical mapping systems. Diagnostic catheters help in measuring electrical impulses in the heart, while ablation catheters are used to deliver energy to specific areas to treat abnormal heart rhythms. Mapping systems provide real-time visualization of the heart's electrical activity, aiding in accurate diagnosis and precise treatment.

The advancement of electrophysiology devices has revolutionized cardiac care, allowing for minimally invasive procedures like catheter-based ablations. These procedures offer patients an alternative to traditional open-heart surgery, significantly reducing recovery time and improving outcomes. As cardiac conditions become more prevalent, the demand for electrophysiology devices is expected to grow, making them indispensable tools in modern cardiovascular medicine.

How does the Increasing Adoption of Catheter Ablation Procedures Surge the Growth of the Electrophysiology Devices Market?

The growing preference for minimally invasive procedures is boosting the adoption of catheter ablation, a key application of electrophysiology devices. A study published in JAMA Network Open in 2021 found that the use of catheter ablation for atrial fibrillation increased by 51% between 2010 and 2018 in the United States. Rising healthcare expenditure and improving healthcare infrastructure. Increased healthcare spending, particularly in emerging economies, is facilitating the adoption of advanced electrophysiology devices. The World Bank reports that global healthcare expenditure as a percentage of GDP increased from 9.7% in 2010 to 9.9% in 2019, indicating a growing investment in healthcare technologies.

Expanding applications in out-of-hospital settings. The increasing use of portable and wearable electrophysiology devices for remote patient monitoring is opening new market opportunities. According to a report by Verified Market Research, the Remote Patient Monitoring Market, which includes cardiac monitoring devices, was valued at USD 41.77 Billion in 2023 and is expected to reach USD 158.39 Billion by 2032, with a growing CAGR of 20% from 2026 to 2032. In addition, the continuous innovations in electrophysiology technologies are expanding the capabilities and applications of these devices. The FDA approved 132 new medical devices in 2021, many of which were in the cardiovascular space.

How Does the High Cost of Electrophysiology Procedures and Devices Impede the Growth of the Electrophysiology Devices Market?

The expensive nature of electrophysiology procedures and devices can limit market growth, especially in developing countries. According to a study published in the Journal of Atrial Fibrillation in 2021, the average cost of catheter ablation for atrial fibrillation in the United States ranged from $18,000 to $32,000, depending on the technology used and the healthcare setting. The lack of trained professionals to perform complex electrophysiology procedures restrains market expansion. A 2022 report by the Heart Rhythm Society stated that there were only about 3,500 board-certified cardiac electrophysiologists in the United States, serving a population of over 330 million. This translates to approximately 1 electrophysiologist per 94,000 people, indicating a significant shortage.

The potential for adverse events during electrophysiology procedures can deter some patients and healthcare providers. A large-scale study published in the European Heart Journal in 2020 found that the overall complication rate for catheter ablation procedures was 5.5%, with 1.7% of patients experiencing major complications. Lengthy and complex regulatory pathways for new electrophysiology devices slow down market growth. The U.S. FDA reported in its 2022 annual performance report that the average time to decision for premarket approval (PMA) applications for medical devices was 365 days. This extended timeline significantly delays the introduction of new electrophysiology technologies to the market.

Category-Wise Acumens

How does the Increasing Heart Failure Incidence in the Growing Aging Population Surge the Growth of the Ablation Catheter Segment?

The ablation catheter segment holds a dominant position in the electrophysiology devices market, driven by its critical role in managing irregular heartbeats that are unresponsive to medication. Ablation catheters are utilized to perform procedures such as radiofrequency (RF) ablation, cryoablation, and pulse field ablation, each offering distinct methods to target and treat abnormal electrical pathways in the heart. The rising incidence of heart failure and arrhythmias, particularly in aging populations. As the elderly are more susceptible to cardiovascular diseases, the demand for effective and reliable electrophysiology treatments, such as ablation catheters, is expected to surge during the forecast period.

The growing awareness of the reliability and success rates of electrophysiology procedures, coupled with continuous advancements in electrophysiology (EP) technology, has significantly boosted the adoption of these devices. Minimally invasive procedures have become increasingly popular, as they offer shorter recovery times, fewer complications, and better patient outcomes compared to traditional open-heart surgeries. Ablation catheters are at the forefront of this shift, as they provide precise, safe, and effective treatment options for a wide range of arrhythmias.

How do the Rising Valvular Heart Disease and High Blood Pressure Cases Foster the Growth of the Atrial Fibrillation (AF) Segment?

The atrial fibrillation (AF) segment is emerging as a dominant in the electrophysiology devices market, driven by the rising incidence of risk factors such as valvular heart disease, high blood pressure, coronary artery disease, and cardiomyopathy, all closely linked to AF. With the global prevalence of AF steadily increasing, there is growing awareness of its severe complications, including stroke, which has heightened the demand for effective treatment options. One of the most impactful treatments is catheter ablation, and its widespread adoption is playing a pivotal role in driving the growth of this segment.

The integration of combination therapies, where electrophysiology devices are used alongside medications to manage various arrhythmias, is further shaping market trends. This multifaceted approach not only improves treatment outcomes but also boosts demand for advanced electrophysiology devices. Additionally, ongoing research into expanding the scope of ablation procedures for arrhythmias beyond AF is expected to create new growth opportunities. As more indications for electrophysiology procedures emerge, niche segments within the market are likely to experience increased investment and innovation. The prominence of AF treatments, particularly catheter ablation, and the continuous advancements in technology ensure that the AF segment will continue to dominate the electrophysiology devices market in the coming years.

How did the High Prevalence of Cardiovascular Diseases and Robust Healthcare Infrastructure Escalate the Growth of the Electrophysiology Devices Market in North America?

The increasing incidence of cardiovascular diseases, especially atrial fibrillation, is a major driver for the electrophysiology devices market in North America. According to the American Heart Association's 2022 Heart Disease and Stroke Statistics update, an estimated 12.1 million people in the United States are projected to have atrial fibrillation by 2030. This represents a significant increase from the 5.2 million cases reported in 2010, indicating a growing need for electrophysiology devices and procedures.

North America's advanced healthcare system and substantial healthcare spending contribute significantly to the growth of the electrophysiology devices market. The Centers for Medicare & Medicaid Services (CMS) reported that U.S. healthcare spending grew 2.7% in 2021 to reach USD 4.3 Trillion, or $12,914 per person. This high level of healthcare expenditure facilitates the adoption of advanced medical technologies, including electrophysiology devices.

The growing preference for minimally invasive electrophysiology procedures is driving market growth in North America. A study published in the Journal of the American College of Cardiology in 2021 reported that the use of catheter ablation for atrial fibrillation in the United States increased by 26% between 2016 and 2020. The study also found that minimally invasive ablation procedures were associated with shorter hospital stays and lower complication rates compared to traditional surgical approaches, further driving their adoption.

How does the High Prevalence of Cardiovascular Diseases and Increasing Life Expectancy Accelerate the Growth of the Electrophysiology Devices Market in Europe?

The increasing incidence of cardiovascular diseases, especially atrial fibrillation, is driving the demand for electrophysiology devices in Europe. According to the European Society of Cardiology's 2021 Cardiovascular Disease Statistics, over 11 million people in Europe were living with atrial fibrillation in 2020. The report projected this number to increase by 70% by 2030, reaching nearly 17 million cases. This significant growth in atrial fibrillation cases is expected to boost the demand for electrophysiology devices and procedures in the region.

Europe's aging population and rising life expectancy are contributing to the growth of the electrophysiology devices market. Eurostat reported in 2022 that the proportion of people aged 65 years and over in the EU is projected to increase from 20.8% in 2021 to 31.3% by 2100. This demographic shift is likely to increase the incidence of cardiac arrhythmias, driving the demand for electrophysiology devices and procedures.

The European market is seeing a growing adoption of advanced electrophysiology technologies and minimally invasive procedures. A study published in the European Heart Journal in 2023 reported that the number of catheter ablation procedures for atrial fibrillation in Europe increased by 15% between 2019 and 2022. The study also noted that centers performing these procedures grew from 498 to 579 during the same period, indicating a widespread adoption of advanced electrophysiology techniques across the continent.

Competitive Landscape

The Electrophysiology Devices Market is a highly competitive landscape, driven by factors such as technological advancements, increasing prevalence of heart diseases, and growing demand for minimally invasive procedures. Several key players operate in this market, offering a range of products and services to meet the diverse needs of healthcare providers and patients.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the electrophysiology devices market include:

• Siemens AG
• Medtronic Plc
• Abbot Laboratories
• GE Healthcare
• Boston Scientific Corporation
• Biosense Webster, Inc.
• Nihon Kohden Corporation
• Biotronik SE & CO. KG
• Microport Scientific Corporation
• Koninklijke Philips N.V.

Latest Developments:

• In March 2021, Beaumont Health announced the launch of a new atrial fibrillation ablation technique to determine if pulsed field ablation may be used to treat individuals with irregular heartbeats.

Electrophysiology Devices Market, By Category

• Type:
• Ablation Catheters
• Diagnostic Catheters
• Laboratory Devices
• Mapping System
• Accessories
• Indication:
• Atrial Fibrillation
• Supraventricular Tachycardia (SVT)
• Ventricular Tachycardia
• End-Use:
• Hospitals
• Ambulatory Surgical Centers
• Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources
• 3.5 Market attractiveness

4 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE

• 5.1 Overview
• 5.2 Ablation Catheters
• 5.3 Diagnostic Catheters
• 5.4 Laboratory Devices
• 5.5 Mapping System
• 5.6 Accessories
• 5.7 Others

6 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET, BY INDICATION

• 6.1 Overview
• 6.2 Atrial Fibrillation
• 6.3 Supraventricular Tachycardia (SVT)
• 6.4 Ventricular Tachycardia
• 6.5 Others

7 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET, BY END-USE

• 7.1 Overview
• 7.2 Hospitals
• 7.3 Ambulatory Surgical Centers
• 7.4 Others

8 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies
• 9.4 ACE Matrix

10 COMPANY PROFILES

• 10.1 Siemens AG
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Medtronic Plc
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Abbot Laboratories
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 GE Healthcare
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Boston Scientific Corporation
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Biosense Webster, Inc.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Nihon Kohden Corporation
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Biotronik SE & CO. KG
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Koninklijke Philips N.V.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Microport Scientific Corporation
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research